异质性肿瘤模型临床前剂量反应实验的样本量计算
该研究开发了一种基于蒙特卡洛方法的样本量估算工具,用于比较性1:1两臂前瞻性肿瘤控制实验。以FaDu头颈鳞癌模型为例,每组7个剂量水平各需10只动物,可检测DMF为1.25(power=0.82,总140只);六种肺癌模型异质性队列则每组11个剂量水平各需21只(power=0.81,总462只),较六个单独实验减少50%以上动物数。
要点
- 异质性队列分析较单独肿瘤控制实验可减少50%以上所需动物数
- FaDu模型检测DMF=1.25需每组7剂量水平×10只(总140只,power=0.82)
- 六种肺癌异质性队列检测DMF=1.25需每组11剂量水平×21只(总462只,power=0.81)
核心结论
- 提出了一种用于异质性肿瘤群体中比较性肿瘤控制实验的动物数量估算方法,并允许实验臂纳入不同治疗作为个体化策略。
- 该软件公开可用,可基于逻辑回归规划S形剂量反应曲线的比较。
研究设计与样本
- 开发了基于蒙特卡洛的方法,用于估算比较性1:1两臂前瞻性肿瘤控制实验的样本量。
- 基于重复逻辑回归分析、预设剂量水平、纳入肿瘤模型的剂量反应曲线假设及剂量修饰因子(DMF),计算给定每组动物数下的检验效能。
主要发现
- FaDu头颈鳞癌模型简单肿瘤控制实验中,每组7个剂量水平各需10只动物,可检测DMF为1.25,power为0.82(无脱落,总140只)。
- 六种不同肺癌模型组合的异质性群体复杂实验中,每组11个剂量水平各需21只动物,可检测DMF为1.25,power为0.81(无脱落,总462只)。
- 分析异质性队列较六个单独肿瘤控制实验减少所需动物数超过50%。
关键数值与推荐
- FaDu模型:DMF=1.25,power=0.82,每组7个剂量水平×10只,总140只(无脱落)。
- 六种肺癌异质性队列:DMF=1.25,power=0.81,每组11个剂量水平×21只,总462只(无脱落)。
临床怎么用
- 可用于规划基于逻辑回归的S形剂量反应曲线比较的临床前肿瘤控制实验样本量。
- 支持在异质性肿瘤模型队列中估算比较性两臂实验所需动物数,并可纳入不同治疗作为个体化实验臂设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In preclinical radio-oncological research, local tumour control is considered the most relevant endpoint as it reflects the inactivation of cancer stem cells. Preclinical tumour-control assays may compare dose-response curves between different radiotherapy strategies, e.g., assessing additional targeted drugs and immunotherapeutic interventions, or between different radiation modalities. To mimic the biological heterogeneity of human tumour populations and to accommodate for approaches of personalized oncology, preclinical studies are increasingly performed combining larger panels of tumour models. For designing the study protocols and to obtain reliable results, prospective sample-size planning has to be developed that accounts for such heterogeneous cohorts. METHODS: A Monte-Carlo-based method was developed to estimate the sample size of a comparative 1:1 two-arm prospective tumour-control assay. Based on repeated logistic regression analysis, pre-defined dose levels, assumptions on the dose-response curves of the included tumour models and on the dose-modifying factors (DMF), the power is calculated for a given number of animals per dose group. RESULTS: Two applications are presented: (i) For a simple tumour-control assay with the head and neck squamous cell carcinoma (HNSCC) model FaDu, 10 animals would be required for each of 7 dose levels per arm to reveal a DMF of 1.25 with a power of 0.82 without drop out (total: 140 animals). (ii) In a more complex experiment combining six different lung tumour models to a heterogeneous population, 21 animals would be required for each of 11 dose levels per arm to reveal a DMF of 1.25 with a power of 0.81 without drop out (total: 462 animals). Analyzing the heterogeneous cohort reduces the required animal number by more than 50% compared to six individual tumour-control assays. CONCLUSION: An approach for estimating the required animal number for comparative tumour-control assays in a heterogeneous population is presented, allowing also the inclusion of different treatments as a personalized approach in the experimental arm. The software is publicly available and can be applied to plan comparisons of sigmoidal dose-response curves based on logistic regression.
引用
- Ciecior W, Ebert N, Borgeaud N, et al. Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models. Radiother Oncol. 2021. PMID: 33667590. doi:10.1016/j.radonc.2021.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。